Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
Ontology highlight
ABSTRACT: In this national Phase I dose-escalation study the safety and tolerability of AP 12009 is evaluated in adult patients with advanced tumors known to overproduce TGF-β2, who are not or no longer amenable to established therapies.
DISEASE(S): Melanoma,Colorectal Neoplasms,Pancreatic Cancer,Pancreatic Neoplasms,Neoplasms
PROVIDER: 2067971 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA